Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma

Muhammed H Elnaggar; Abdelrahman I Abushouk; Ahmed H E Hassan; Hadeer M Lamloum; Amira Benmelouka; Shurouk A Moatamed; Hossam Abd-Elmegeed; Somia Attia; Aya Samir; Nouran Amr; Dina Johar; Samy Zaky

doi:10.1016/j.semcancer.2019.08.016

Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma

Semin Cancer Biol. 2021 Feb:69:91-99. doi: 10.1016/j.semcancer.2019.08.016. Epub 2019 Aug 14.

Authors

Affiliations

¹ Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt. Electronic address: Muhamedelnaggar@sci.asu.edu.eg.
² Medical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: abdelrahman.abushouk@med.asu.edu.eg.
³ Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address: ahmed_hassan@mans.edu.eg.
⁴ Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: Hadeerm580@gmail.com.
⁵ Faculty of Medicine, University of Algiers, Algiers, Algeria. Electronic address: amira.yasmine.benmelouka@gmail.com.
⁶ Biotechnology Department, Faculty of Science, Cairo University, Giza, Egypt. Electronic address: Shorok.atef@msa.edu.eg.
⁷ Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address: Husamhasan9090@gmail.com.
⁸ Microbiology and Biochemistry Department, Faculty of Science, Helwan University, Helwan, Egypt. Electronic address: somiaattia461@gmail.com.
⁹ Biotechnology Department, Faculty of Science, Cairo University, Cairo, Egypt. Electronic address: ayasamirghanem333@gmail.com.
¹⁰ Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tanta University, Tanta, Egypt. Electronic address: nouranamr161@gmail.com.
¹¹ Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, 12588, Giza, Egypt. Electronic address: umjohar@myumanitoba.ca.
¹² Department of Tropical Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Electronic address: samyzs55@yahoo.com.

PMID: 31421265
DOI: 10.1016/j.semcancer.2019.08.016

Abstract

The effectiveness of chemotherapy in hepatocellular carcinoma (HCC) is restricted by chemo-resistance and systemic side effects. To improve the efficacy and safety of chemotherapeutics in HCC management, scientists have attempted to deliver these drugs to malignant tissues using targeted carriers as nanoparticles (NPs). Among the three types of NPs targeting (active, passive, and stimuli-responsive), active targeting is the most commonly investigated in HCC treatment. Despite the observed promising results so far, clinical research on nanomedicine targeting for HCC treatment still faces many challenges.These include batch-to-batch physicochemical properties' variations, limiting large scale production and insufficient data on human and environmental toxicities. This review summarized the characteristics of different nanocarriers, ligands, targeted receptors on HCC cells and provided recommendations to overcome the challenges, facing this novel line of treatment for HCC.

Keywords: Active targeting; Chemotherapy; Hepatocellular carcinoma; Nanomedicine; Nanoparticles.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / administration & dosage*
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / pathology
Drug Delivery Systems*
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Nanomedicine*
Nanoparticles / administration & dosage*
Nanoparticles / chemistry

Substances

Antineoplastic Agents